SCHEDULE 13D/A: GoodRx Holdings to Repurchase $12.6 Million in Class A Shares from Spectrum Equity Funds

GoodRx Holdings, Inc. has entered into an agreement to repurchase 3 million Class A shares for $12.6 million from several Spectrum Equity funds, reducing their beneficial ownership percentage.

Summary

• GoodRx Holdings, Inc. (the "Issuer") is repurchasing 3,000,000 Class A Common Stock shares from Spectrum Equity VII, L.P., Spectrum VII Investment Managers' Fund, L.P., and Spectrum VII Co-Investment Fund, L.P. (the "Selling Stockholders").
• The total net proceeds for the Selling Stockholders from this repurchase will be $12,600,000.
• The transaction, known as the "March 2025 Spectrum Repurchase," is expected to close on March 21, 2025.
• Following the repurchase, the Reporting Persons (Spectrum Equity entities) will beneficially own an aggregate of 22,905,133 shares, representing 17.7% of the total outstanding Class A Shares (calculated assuming 129,645,461 Class A Shares outstanding).
• This filing is Amendment No. 4 to the original Schedule 13D filed on June 1, 2021, updating the beneficial ownership information.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The share repurchase indicates a capital allocation decision by GoodRx, which can be viewed positively by investors as it reduces the share count. For Spectrum Equity, it represents a partial monetization of their investment. No negative surprises or adverse events are disclosed in the filing.

Positives

• For GoodRx: The share repurchase can reduce the number of outstanding shares, potentially increasing earnings per share and signaling management's confidence in the company's valuation.
• For Spectrum Equity: The transaction allows for the monetization of a portion of their investment in GoodRx Holdings, Inc.

Negatives

• For GoodRx: The company is spending $12.6 million in cash, which could otherwise be used for growth initiatives, debt reduction, or other corporate purposes.
• For Spectrum Equity: A reduction in their ownership stake, which could be interpreted as a partial exit or reduced conviction, although it is a common private equity strategy.

Risks

• The March 2025 Spectrum Repurchase is expected to close on March 21, 2025; however, any unforeseen circumstances could potentially delay or prevent the closing of the transaction.

Future Outlook

The document primarily reports a specific transaction (share repurchase agreement) and its expected closing date. It does not provide broader forward-looking statements or guidance on the company's future performance, strategic direction, or financial outlook beyond this specific event.

Industry Context

This transaction represents a specific share repurchase by GoodRx Holdings, Inc. from a significant institutional investor, Spectrum Equity. While share repurchases are a common capital allocation strategy across various industries, this filing does not provide broader industry trends or competitive analysis. It reflects a decision by GoodRx to reduce its outstanding share count and a partial monetization event for Spectrum Equity.

Legal Proceedings

• The Reporting Persons and any Related Persons have not been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors) during the last five years.
• Neither the Reporting Persons nor any Related Persons were a party to a civil proceeding of a judicial or administrative body of competent jurisdiction that resulted in a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding any violation with respect to such laws, during the last five years.

Related Party Transactions

• GoodRx Holdings, Inc. is repurchasing 3,000,000 Class A shares from Spectrum Equity funds, which are significant beneficial owners of the company, making this a related party transaction.

Stakeholder Impact

• Shareholders: The repurchase reduces the number of outstanding shares, which could potentially increase earnings per share for remaining shareholders and may signal management's confidence in the company's valuation.
• Spectrum Equity (Selling Stockholders): This transaction allows them to monetize a portion of their investment in GoodRx Holdings, Inc.

Next Steps

• Closing of the March 2025 Spectrum Repurchase, which is expected to occur on March 21, 2025.

Key Dates

Recommendation

Keywords

GoodRx Holdings, Spectrum Equity, Share Repurchase, Class A Common Stock, SEC Filing, Schedule 13D, Beneficial Ownership, Stock Purchase Agreement, GRX